Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06216054
Other study ID # LY03015/CT-CHN-102
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date December 23, 2023
Est. completion date August 14, 2024

Study information

Verified date January 2024
Source Luye Pharma Group Ltd.
Contact Huafang Li, Doctor
Phone +8618017311256
Email lhlh_5@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single-center, randomized, double-blind, placebo-controlled, multiple-ascending doses trial to evaluate the safety, tolerability and pharmacokinetic of LPM3770164 sustained-release tablets orally administered in healthy subjects under fasting state, providing the rationale information for later clinical trials.


Recruitment information / eligibility

Status Recruiting
Enrollment 48
Est. completion date August 14, 2024
Est. primary completion date August 14, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: 1. Subject who voluntarily participate and sign the informed consent form; 2. Healthy male/female volunteers aged 18 to 45 years; 3. Body weight = 50.0 kg for men and = 45.0 kg for women, and body mass index (BMI) 18.5 ~ 26.0 kg/m2, inclusive; 4. Able to comply with the lifestyle restrictions. Exclusion Criteria: 1. Subject has a history of allergy to any component of the investigational drug or similar drugs, or allergic constitution; 2. Subject has a current or past medical history that may affect the clinical trial or dysfunction, including but not limited to the past or current respiratory system, circulatory system, digestive system, urinary system, reproductive system, nervous system, endocrine system, immune system, motor system, blood system, psychiatry/ psychology, dermatology and other clinically serious diseases or chronic diseases; or any other diseases that may interfere with the test results; 3. Any surgical condition or condition may significantly affect the absorption, distribution, metabolism and excretion of the drug, or may pose a hazard to the subjects;. 4. Subject has a history of self-mutilation; or at risk of suicide; 5. Subject has a history of surgery within 3 months prior to administration, or failure to recover from surgery, or having an expected surgical plan during the trial; 6. Subject has abnormal vital signs, laboratory abnormalities, and ECGs; 7. Subject has used any of over-the-counter products within 7 days or prescription medications within 28 days prior to dosing; 8. Subject positive for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab), HIV antibody (HIV-Ab), or syphilis seroreactivity (Trust); 9. Subject has a history of alcohol abuse within 1 year or positive alcohol breath test results; 10. Subject has a history of substance abuse within 1 year or a positive urine drug screen; 11. Subject who has daily smoking of = 5 cigarettes within 3 months; 12. Subject who has special requirements for food, cannot comply with the unified diet or have dysphagia; 13. Subject who has consumption of xanthine-rich foods or beverages (such as tea, coffee, cola, or chocolate) within 3 days prior to administration; 14. Subject who has consumption of food or beverages containing grapefruit within 7 days prior to administration; 15. Subject who has participated in other clinical trials within 3 months before administration; 16. Subject has used blood products or being blood donor or blood loss within 3 months; 17. Pregnant, lactating women, or positive pregnancy test; 18. Subject who refusal to contraception, or plan to donate sperm or ovums; 19. Other conditions which would make participation in the study unsuitable.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
LPM3770164 sustained release tablet
administrated orally
LPM3770164 sustained release tablet simulant
administrated orally

Locations

Country Name City State
China Shanghai Mental Health Center Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Luye Pharma Group Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Treatment-emergent adverse event Number of participants with treatment-emergent adverse event will be summarized by Group, System Organ Classification (SOC), Preferred Term (PT), severity and the relationship with treatment. from baseline to day 37
Secondary Peak Plasma Concentration (Cmax) from day 1 to day 24
Secondary Area Under the Curve from time 0 to 24 hours (AUC0-24) from day 1 to day 24
Secondary Area Under the Curve from time 0 to the last measurable concentration (AUC0-t) from day 1 to day 24
Secondary Area Under the Curve from time 0 extrapolated to infinity (AUC0-inf) from day 1 to day 24
Secondary Time to maximum concentration (Tmax) from day 1 to day 24
Secondary Half-life (t1/2) from day 1 to day 24
Secondary ECG QTc Interval from baseline to day 37
See also
  Status Clinical Trial Phase
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Not yet recruiting NCT04429230 - Non-invasive Brain Stimulation in Huntington's Disease N/A
Recruiting NCT05032196 - Study of WVE-003 in Patients With Huntington's Disease Phase 1/Phase 2
Recruiting NCT03599076 - Wearable Sensors for Quantitative Assessment of Motor Impairment in Huntington's Disease Huntington's Disease
Terminated NCT04617860 - Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease Phase 1/Phase 2
Completed NCT05748288 - Development of the Virtual Unified Huntington's Disease Rating Scale
Not yet recruiting NCT05360082 - Comparison Between [11C]UCB-J and [18F]SynVest-1 PET in HD.
Not yet recruiting NCT04370470 - Development of Assessments for Later Stage HD
Recruiting NCT01834053 - Safety and Efficacy of Bone Marrow Derived MNCs for Treatment of Cells for the Treatment of Hunting Tons Chorea. Phase 1/Phase 2
Completed NCT01458470 - A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease Phase 2
Completed NCT01357681 - Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study) Phase 2
Completed NCT00980694 - Bioavailability of Ubiquinol in Huntington Disease Phase 1
Completed NCT00146211 - TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease Phase 3
Recruiting NCT01412125 - Study of Biomarkers That Predict the Evolution of Huntington's Disease N/A
Completed NCT00075140 - Family Health After Predictive Huntington Disease (HD) Testing Phase 3
Recruiting NCT04818060 - Preparing for Prevention of Huntington's Disease (PREVENT-HD)
Active, not recruiting NCT04698551 - NIPD on cffDNA for Triplet Repeat Diseases
Not yet recruiting NCT04301726 - Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated With HD Phase 1
Completed NCT03421327 - Genetic Risk: Whether, When, and How to Tell Adolescents
Recruiting NCT03296176 - Metabolomic Study in Huntington's Disease (METABO-HD) N/A